Cancer tech Patent Infringment: Gilead Sciences told to pay 1.2 billion dollars to Bristol-Myers Squibb Medical Dialogues Bureau11 April 2020 8:26 AM GMT USA: A federal judge increased to $1.2 billion the damages that Gilead Sciences Inc must pay to Bristol-Myers Squibb Co in a patent infringement...
More drugmakers including Gilead, Biogen, BMS to hike US prices for 50 drugs Medical Dialogues Bureau2 Jan 2020 9:18 AM GMTNew Delhi: Drugmakers including Bristol-Myers Squibb Co (BMY.N), Gilead Sciences Inc (GILD.O), and Biogen Inc (BIIB.O) hiked U.S. list prices on more...
Merck loses bid to revive over Rs 18 crore patent verdict against Gilead Farhat Nasim31 Oct 2019 9:57 AM GMTIn 2016, a jury returned a verdict that Gilead Science's hepatitis C drugs Sovaldi and Harvoni infringed the patent, which Merck acquired when it...
Gilead licenses respiratory, herpes antiviral research programs from Novartis Medical Dialogues Bureau23 July 2019 3:45 AM GMTUnder the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets....
Gilead to raise stake in Belgian Biotech Galapagos in USD 5.1 billion deal: Report Medical Dialogues Bureau15 July 2019 4:00 AM GMTThe deal is the largest Gilead has executed since new Chief Executive Officer Dan O'Day took the reins in March as he attempts to bolster the San...
Gilead Sciences chooses Chengdu Hi-tech Zone for Western China Operation Center project Medical Dialogues Bureau12 July 2019 3:40 AM GMTEstablished in 1987 and headquartered in California, Gilead Sciences is one of the top 10 pharmaceutical companies in the world. As a pioneer in...
Cipla gets USFDA nod for Ambrisentan tablets to treat pulmonary arterial hypertension Farhat Nasim30 April 2019 4:30 AM GMTCipla's Ambrisentan tablets 5 mg and 10 mg is AB-rated generic therapeutic equivalent version of Gilead Sciences Inc's Letairis.New Delhi: Drug major...
Novartis Kymriah wins UK backing after initial lymphoma snub Medical Dialogues Bureau3 Feb 2019 4:30 AM GMT"Today's positive announcement regarding access to Kymriah treatment in England and Wales was secured as a result of our close working collaboration...
Gilead wins reversal of 2.54 billion dollars hepatitis C drug patent verdict Ruby Khatun Khatun19 Feb 2018 4:15 AM GMTA federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs...
Gene therapy for rare form of blindness wins US approval Ruby Khatun Khatun21 Dec 2017 4:34 AM GMTWASHINGTON: U.S. health officials on Tuesday approved the nation's first gene therapy for an inherited disease, a treatment that improves the sight of...
Novartis CAR-T therapy leads to durable response in lymphoma study Ruby Khatun Khatun11 Dec 2017 5:15 AM GMTPatients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy...
Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 5:00 AM GMTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
